Recombinant Human IFN-alpha/beta R2 Fc Chimera Protein, CF

Recombinant Human IFN-alpha/beta R2 Fc Chimera (Catalog #4015-AB) inhibits the anti-viral activity of Recombinant Human IFN-beta (Catalog # 8499-IF). The ED50 for this effect is 0.1‑0.6 μg/mL.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human IFN-alpha/beta R2 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its ability to inhibit Type-I IFN-mediated anti-viral activity. The ED₅₀ for this effect, as measured by inhibition of Recombinant Human IFN‑ beta (Catalog # 8499-IF) , is 0.1-0.6 μg/mL
• Source: Mouse myeloma cell line, NS0-derived human IFN-alpha/beta R2 protein
  

  Human IFN-alpha / beta R2 (Ile27-Lys243) Accession # P48551	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: P48551
• N-terminal Sequence: Ile27
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Gene: IFNAR2
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Endotoxin Note: <0.01 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 51.3 kDa (monomer).
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 71-76 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human IFN-alpha/beta R2 Fc Chimera Protein, CF

• beta receptor10
• human interferon alpha
• human interferon alpha/beta receptor
• IFNABR
• IFN-alpha binding protein
• IFN-alpha/beta R2
• IFN-alpha/beta receptor 2
• IFN-alpha-REC
• IFNAR2
• IFN-aR2
• IFNARB
• IFNbR2
• IFN-bR2
• IFN-R
• IFN-R-2
• interferon (alpha, beta and omega) receptor 2
• Interferon alpha binding protein
• interferon alpha/beta receptor 2
• interferon-alpha/beta receptor beta chain
• Type I interferon receptor 2

Background

IFN-alpha / beta R2, also known as IFNAR2, is a 100 kDa glycoprotein in the class II cytokine receptor family. These proteins form heterodimeric receptor complexes that transduce signals from the interferon, IL-10, and IL-28 families of cytokines (1, 2). IFN-alpha / beta R2, in association with IFN-alpha / beta R1, is required for mediating the antiviral, antiproliferative, and apoptotic effects of the type I interferons IFN-alpha and IFN-beta . IFN-alpha / beta R2 is the principal ligand binding subunit of the receptor. Ligand binding is stabilized by the subsequent association with IFN-alpha / beta R1, resulting in the formation of a signaling ternary receptor complex (3, 4). Mature human IFN-alpha / beta R2 consists of a 217 amino acid (aa) extracellular domain (ECD) with two fibronectin type III repeats, a 21 aa transmembrane segment, and a 251 aa cytoplasmic domain. Alternate splicing generates a secreted isoform that corresponds to the ECD and a 50 kDa transmembrane isoform with a substituted and truncated cytoplasmic region (5, 6). The short isoform is impaired in its ability to activate signaling molecules and functions as a dominant negative receptor subunit (7 - 9). IFN-alpha / beta R2 is also subject to presenilin-dependent intramembrane proteolysis, resulting in the liberation of nearly the entire ECD as well as the cytoplasmic domain which migrates to the nucleus and can inhibit gene transcription (10). High concentrations of soluble IFN-alpha / beta R2 bind and neutralize IFN-alpha and IFN-beta , while lower concentrations prolong the antiviral activity of circulating IFN-beta but not IFN-alpha (11). Human but not mouse IFN-alpha / beta R2 constitutively associates with STAT4, which may account for species specific differences observed in type I interferon responses (12). Within the ECD, human IFN-alpha / beta R2 shares 63%, 60%, and 48% aa sequence identity with bovine, mouse, and ovine IFN-alpha / beta R2, respectively.

1. Langer, J.A. et al. (2004) Cytokine Growth Factor Rev. 15:33.
2. Pestka, S. et al. (2004) Immunol. Rev. 202:8.
3. Lamken, P. et al. (2004) J. Mol. Biol. 341:303.
4. Arduini, R.M. et al. (1999) Prot. Sci. 8:1867.
5. Lutfalla, G. et al. (1995) EMBO J. 14:5100.
6. Novick, D. et al. (1995) J. Leukocyte Biol. 57:712.
7. Pfeffer, L.M. et al. (1997) J. Biol. Chem. 272:11002.
8. Gazziola, C. et al. (2005) Int. J. Oncol. 26:129.
9. Kotenko, S.V. and S. Pestka (2000) Oncogene 19:2557.
10. Saleh, A.Z.M. et al. (2004) Oncogene 23:7076.
11. McKenna, S.D. et al. (2004) J. Interferon Cytokine Res. 24:119.
12. Tyler, D.R. et al. (2007) Mol. Immunol. 44:1864.

Publications for IFN-alpha/beta R2 (4015-AB)(3)

Publications using 4015-AB

• BD Harris, J Schreiter, M Chevrier, JL Jordan, MR Walter Human Interferon-&amp;epsilon; and interferon-? exhibit low potency and low affinity for cell surface IFNAR and the poxvirus antagonist B18R J. Biol. Chem., 2018-08-31;0(0):. 2018-08-31 [PMID: 30171073] (Bioassay, Human)
• S Soonthornv, A Rodriguez-, Y Zhou, F Galvez, NJ Huffmaster, S Tripathi, VR Balasubram, A Inoue, E de Castro, H Moulton, DA Stein, MT Sánchez-Ap, PD De Jesus, Q Nguyen, R König, NJ Krogan, A García-Sas, SM Yoh, SK Chanda Systems-based analysis of RIG-I-dependent signalling identifies KHSRP as an inhibitor of RIG-I receptor activation Nat Microbiol, 2017-03-01;2(0):17022. 2017-03-01 [PMID: 28248290] (Bioassay, Human)
• Li M, Rao C, Pei D, Wang L, Li Y, Gao K, Wang M, Wang J Novaferon, a novel recombinant protein produced by DNA-shuffling of IFN-alpha, shows antitumor effect in vitro and in vivo. Cancer Cell Int, 2014-01-27;14(1):8. 2014-01-27 [PMID: 24467885] (Surface Plasmon Resonance)

Bioinformatics

• Gene Symbol: IFNAR2
• Uniprot:
  • P48551(Human)